Kesselheim Aaron S
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
AAPS J. 2007 Aug 3;9(3):E306-11. doi: 10.1208/aapsj0903033.
Though patents are effective tools for promoting innovation and protecting intellectual property in the pharmaceutical sciences, there has been growing concern about 2 important ways that patents in this field can have a negative effect on patient care and the practice of medicine. First, inventors can seek and receive patents on pharmaceutical products or research tools that stretch the statutory requirements for patenting. Second, patent holders in the pharmaceutical market can use legal loopholes or aspects of the patent registration system to extend exclusivity for inventions beyond what was anticipated by the Patent Act or subsequent legislation. The monopoly control bestowed by such inappropriate patents or manipulation of the patent system can limit options available to patients, increase the cost of health care delivery, and make cooperative research more difficult. In response, several different government and market-based efforts have emerged to promote more equitable patent policy in health care that encourages dissemination of ideas while still supporting the development of innovative products.
尽管专利是促进制药科学领域创新和保护知识产权的有效工具,但人们越来越担心该领域的专利会通过两种重要方式对患者护理和医学实践产生负面影响。首先,发明人可能会寻求并获得关于药品或研究工具的专利,而这些专利超出了专利的法定要求。其次,制药市场中的专利持有人可能会利用法律漏洞或专利注册系统的某些方面,将发明的排他性延长至超出《专利法》或后续立法预期的范围。此类不当专利或对专利制度的操纵所赋予的垄断控制可能会限制患者可选择的方案,增加医疗保健服务的成本,并使合作研究变得更加困难。作为回应,已经出现了几种不同的基于政府和市场的努力,以促进医疗保健领域更公平的专利政策,鼓励思想传播,同时仍支持创新产品的开发。